Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation
International Journal of Nanomedicine · 2025
DOI: 10.2147/ijn.s562002 ↗At a glance
Journal article in International Journal of Nanomedicine, 2025. Written by Qiao Zeng and 6 co-authors. Institution: School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China. Major MEDLINE topics: Everolimus, Nanoparticles, Angiogenesis Inhibitors. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 3.0).
Abstract (original language)
Purpose
To develop everolimus-loaded nanosuspensions (EV-sus) for the in vitro and in vivo corneal neovascularization (CNV) treatment.
Results
Everolimus was encapsulated into nanosuspensions using a solvent volatilization technique. The developed nanosuspensions exhibited a drug concentration of 0.96 mg·mL-1, an average particle size of 141.0 ± 1.0 nm, and a zeta potential of -12.2 ± 0.4 mV. C6-labeled EV-sus uptake by Human Corneal Epithelial Cells-Transformed (HCE-T) was time-dependent, energy-dependent, and involved multiple endocytic pathways, including caveolae- and lipid raft-mediated endocytosis, clathrin-mediated endocytosis, and caveolae-mediated endocytosis. The nanosuspensions exhibited efficacy in inhibiting VEGF-induced proliferation, migration, and tube formation in Human Umbilical Vein Endothelial Cells (HUVECs). According to RT-qPCR, the in vivo CNV model showed that EV-sus effectively reduced neovascularization, decreased vascular length and area, and diminished the expression of IL-1, IL-6, MMP-9, VEGF, and TNF-α. Additionally, the rabbit eye irritation test confirmed the safety and tolerability of the formulation.
Conclusion
These findings indicate that EV-sus might be an effective therapy for corneal neovascularization. The formulation exhibits excellent biocompatibility, efficient cellular uptake, and robust anti-angiogenic activity, suggesting its suitability for ocular administration and the potential to mitigate CNV progression with minimal irritation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
- Key Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
ORCID profiles: Qiao Zeng, Wenying Yu, Qiao Wang
Cite
APA
Zeng, Q., Chen, J., Zhang, H., Yu, W., Xu, H., Wang, Q., & Tang, Z. (2025). Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s562002
Vancouver
Zeng Q, Chen J, Zhang H, Yu W, Xu H, Wang Q, et al. Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s562002
BibTeX
@article{Zeng2025,
author = {Zeng, Qiao and Chen, Jie and Zhang, Han and Yu, Wenying and Xu, Haonan and Wang, Qiao and Tang, Zhan},
title = {Enhanced Everolimus Delivery: Development and Evaluation of a Nanosuspension Formulation},
journal = {International Journal of Nanomedicine},
year = {2025},
doi = {10.2147/ijn.s562002}
}
EUVIMED